{"id":5442,"date":"2010-10-07T11:27:14","date_gmt":"2010-10-07T02:27:14","guid":{"rendered":"http:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/contents\/?p=151"},"modified":"2010-10-07T11:27:14","modified_gmt":"2010-10-07T02:27:14","slug":"2007%e5%b9%b4%e6%a5%ad%e7%b8%be","status":"publish","type":"post","link":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/%e7%a0%94%e7%a9%b6%e7%b4%b9%e4%bb%8b\/5442\/","title":{"rendered":"2007\u5e74\u696d\u7e3e"},"content":{"rendered":"

\u25a0 \u8ad6\u6587\u30fb\u8457\u66f8
\n\u539f\u8457\u8ad6\u6587<\/a>
\n\u7dcf\u8aac\uff0c\u4ed6<\/a>
\n\u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868
\n\u56fd\u969b\u5b66\u4f1a<\/a>
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09<\/a>
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/a>
\n\u25a0 \u8b1b\u6f14<\/a>
\n—————————
\n\u25a0<\/span> \u8ad6\u6587\u30fb\u8457\u66f8<\/strong>
\n<\/a>\u25cf<\/span> \u539f\u8457\u8ad6\u6587
\n1. Sakayama K, Sugawara Y, Kidani T, Miyawaki J, Fujibuchi T, Kamei S, Aizawa J, Yamamoto H. Diagnostic and therapeutic problems of giant cell tumor in the proximal femur. Arch Orthop Trauma Surg 127: 867-872, 2007 [PubMed<\/a>]
\n2. Tagashira H, Arakawa K, Yoshimoto M, Mochizuki T, Murase K, Yoshida H. Improvement of lung abnormality detection in computed radiography using multi-objective frequency processing: Evaluation by receiver operating characteristics (ROC) analysis. Eur J Radiol 65: 473-477, 2008 [PubMed<\/a>]
\n3. Tagashira H, Arakawa K, Yoshimoto M, Mochizuki T, Murase K. Detectability of lung nodules using flat panel detector with dual energy subtraction by two shot method: evaluation by ROC method. Eur J Radiol 64: 279-84, 2007 [PubMed<\/a>]
\n4. Takahashi Y, Murase K, Mochizuki T, Sugawara Y, Maeda H, Kinda A. Simultaneous 3-dimensional resolution correction in SPECT reconstruction with an ordered-subsets expectation maximization algorithm. J Nucl Med Tech 35: 34-38, 2007 [PubMed<\/a>]
\n5. Hiratsuka Y, Miki H, Kikuchi K, Kiriyama I, Mochizuki T, Takahashi Y, Sadamoto K. Sensitivity of an eight-element head array coil in 3 tesla MR imaging. Magnetic Resonance in Medical Science 6: 177-181, 2007 [PubMed<\/a>]
\n6. Ide K, Mogami H, Murakami T, Yasuhara Y, Miyagawa M, Mochizuki T. Detection of lung cancer using single-exposure dual-energy subtraction chest radiography. 25: 195-201, 2007 [PubMed<\/a>]
\n7. Nagao M, Higashino H, Matsuoka H, Kawakami H, Miyagawa M, Mochizuki T, Uemura M, Tokunaga N. Evaluation of acute myocardial infarction with late enhancement pattern on MRI compared with 201-Tl and 99m-Tc HMDP dual SPECT images. Investigative Radiology 42: 765-770, 2007 [PubMed<\/a>]
\n8. Kido T, Kurata A, Higashino H, Sugawara Y, Okayama H, Higaki J, Anno H, Katada K, Mori S, Tanada S, Endo M, Mochizuki T. Cardiac imaging using 256-detector row four-dimensional CT: preliminary clinical report. Radiat Med 25: 38-44, 2007 [PubMed<\/a>]
\n9. Kajihara M, Sugawara Y, Sakayama K, Kikuchi K, Mochizuki T, Murase K. Evaluation of tumor blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy-work in progress. Radiat Med 25: 94-105, 2007 [PubMed<\/a>]
\n10. Kanza R.E, Higashino H, Kido T, Kurata A, Saito M, Sugawara Y, Mochizuki T. Quantitative assessment of regional left ventricular wall thickness and thickening using 16 multidetector-row computed tomography: comparison with cine magnetic resonance imaging. Radiat Med 25: 119-126, 2007 [PubMed<\/a>]
\n11. \u5927\u576a\u91cc\u7e54, \u767d\u5ddd\u6d0b\u4e00, \u76f8\u5f15\u771e\u5e78, \u897f\u5c71\u9686, \u524d\u5ddd\u8061\u4e00, \u83ca\u6c60\u6075\u4e00, \u77f3\u5ddd\u667a\u4e45. \u4e00\u9178\u5316\u70ad\u7d20\u4e2d\u6bd2\u306e\u9045\u767a\u6027\u8133\u75c7\u304bMRI\u306b\u3088\u3063\u3066\u4e88\u6e2c\u3067\u304d\u308b. \u4e2d\u6bd2\u7814\u7a76 20: 253-261, 2007
\n12. \u5bae\u5ddd\u6b63\u7537. \u5fc3\u81d3\u306e\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\uff1a\u85ac\u5264\u8ca0\u8377\u6cd5\u304b\u3089PET\u306b\u3088\u308b\u907a\u4f1d\u5b50\u767a\u73fe\u306e\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u307e\u3067. \u5fc3\u81d3\u6838\u533b\u5b66 9: 28-29, 2007
\n13. \u5bae\u5ddd\u6b63\u7537. PET\/CT\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u30d0\u30a4\u30a2\u30d3\u30ea\u30c6\u30a3\u8a3a\u65ad. \u65b0\u533b\u7642 34: 54-57, 2007 [CiNii<\/a>]
\n14. \u9ad8\u6a4b\u5eb7\u5e78, \u4e94\u5341\u5d50\u535a, \u5e73\u91ce\u90a6\u5f18, \u6cb3\u539f\u7530\u6cf0\u5c0b, \u4e94\u5341\u5d50\u5747, \u6751\u702c\u7814\u4e5f, \u671b\u6708\u8f1d\u4e00. \u653e\u5c04\u6027\u540c\u4f4d\u5143\u7d20\u7b49\u306b\u3088\u308b\u653e\u5c04\u7dda\u969c\u5bb3\u306e\u9632\u6b62\u306b\u95a2\u3059\u308b\u6cd5\u5f8b\u7b49\u306b\u57fa\u3065\u304f\u6821\u6b63\u7528\u7dda\u6e90\u7b49\u306e\u73fe\u72b6\u8abf\u67fb\u306b\u3064\u3044\u3066. \u65e5\u672c\u653e\u5c04\u7dda\u6280\u8853\u5b66\u4f1a\u96d1\u8a8c 63: 335-340, 2007 [CiNii<\/a>]
\n15. \u6771\u91ce \u535a, \u9f4b\u85e4 \u5b9f, \u5ca1\u5c71 \u82f1\u6a39, \u6a9c\u57a3 \u5be6\u7537, \u4e09\u6728 \u5747, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b \u5fd7\u6d25\u6c5f, \u8c9e\u672c \u548c\u5f66. \u865a\u8840\u6027\u5fc3\u75be\u60a3\u306eMRI\u8a3a\u65ad – 3.0T\u30681.5T\u3068\u306e\u6bd4\u8f03 -. \u65e5\u7368\u533b\u5831 52: 18-25, 2007
\n<\/a>\u25cf<\/span> \u7dcf\u8aac\uff0c\u4ed6
\n16. \u5009\u7530\u8056, \u5ca1\u5c71\u82f1\u6a39, \u6867\u57a3\u5be6\u7537, \u57ce\u6238\u8f1d\u4ec1, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u8c9e\u672c\u548c\u5f66, \u672c\u7530\u4fca\u96c4, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f. \u9818\u57df\u5225\u306b\u898b\u308b64\u5217MDCT\u306e\u691c\u67fb\u3068\u8a3a\u65ad\u3000\u5fc3\u30fb\u8840\u7ba1\u9818\u57df\u3000\u5fc3\u30fb\u8840\u7ba1\u9818\u57df\u306b\u304a\u3051\u308b64\u5217MDCT\u306e\u81f3\u9069\u64ae\u5f71\u65b9\u6cd5. INNERVISION 22: 57-61, 2007
\n17. \u5b89\u91ce\u6cf0\u53f2, \u4e09\u7530\u7965\u5bdb, \u6751\u5c71\u548c\u5b8f, \u52a0\u85e4\u826f\u4e00, \u7247\u7530\u548c\u5e83, \u5143\u5c71\u8c9e\u5b50, \u4f50\u85e4\u8cb4\u4e45, \u76bf\u4e95\u6b63\u7fa9, \u671b\u6708\u8f1d\u4e00. \u80ba\u751f\u691c\u7814\u7a76\u4f1a\u30b9\u30c6\u30fc\u30c8\u30e1\u30f3\u30c8. Interventional Radiology 22: 256-261, 2007
\n18. \u5b89\u91ce\u6cf0\u53f2(\u85e4\u7530\u4fdd\u5065\u885b\u751f\u5927\u5b66 \u885b\u751f\u5b66\u90e8\u8a3a\u7642\u653e\u5c04\u7dda\u6280\u8853\u5b66\u79d1), \u4e09\u7530\u7965\u5bdb, \u6751\u5c71\u548c\u5b8f, \u7247\u7530\u548c\u5e83, \u4f50\u85e4\u8cb4\u4e45, \u5143\u5c71\u8c9e\u5b50, \u76bf\u4e95\u6b63\u7fa9, \u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3\u9818\u57df\u306b\u304a\u3051\u308b\u753b\u50cf\u8a3a\u65ad\u6700\u524d\u7dda\u3011 256\u5217CT\u306b\u3088\u308b\u5fc3\u81d3\u306e\u753b\u50cf\u8a3a\u65ad\u6700\u524d\u7dda(\u89e3\u8aac\/\u7279\u96c6). Rad Fan 4: 51-54, 2006
\n19. \u6771\u91ce \u535a. PET\/CT\u306b\u3088\u308bCT\u51a0\u52d5\u8108\u9020\u5f71\u3068\u5fc3\u6a5f\u80fd\u306e\u540c\u6642\u8a55\u4fa1. \u30a4\u30f3\u30ca\u30fc\u30d3\u30b8\u30e7\u30f3 22: 24, 2007
\n20. \u6d25\u7530\u5b5d\u6cbb, \u5e73\u7530\u96c5\u662d, \u5175\u982d\u670b\u5b50, \u6751\u4e0a\u6b63\u54f2, \u671b\u6708\u8f1d\u4e00. \u809d\u786c\u5909\u60a3\u8005\u306b\u304a\u3051\u308b\u751f\u7406\u7684\u98df\u5869\u6c34\u30d5\u30e9\u30c3\u30b7\u30e5\u4f75\u7528\u306e\uff13\u6b21\u5143\u9580\u8108\uff23\uff34\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066. \u6620\u50cf\u60c5\u5831Medical 39: 670-674, 2007
\n21. \u5b89\u91ce\u6cf0\u53f2(\u85e4\u7530\u4fdd\u5065\u885b\u751f\u5927\u5b66 \u885b\u751f\u5b66\u90e8\u8a3a\u7642\u653e\u5c04\u7dda\u6280\u8853\u5b66\u79d1), \u4e09\u7530\u7965\u5bdb, \u6751\u5c71\u548c\u5b8f, \u52a0\u85e4\u826f\u4e00, \u7247\u7530\u548c\u5e83, \u5143\u5c71\u8c9e\u5b50, \u4f50\u85e4\u8cb4\u4e45, \u76bf\u4e95\u6b63\u7fa9, \u671b\u6708\u8f1d\u4e00. \u3010\u80f8\u90e8\u306e\u6700\u65b0\u753b\u50cf\u60c5\u58312007\u3011 Coronary CT angiography\u306e\u73fe\u72b6(\u7dcf\u8aac\/\u7279\u96c6). \u81e8\u5e8a\u653e\u5c04\u7dda 52: 59-65, 2007
\n22. \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u8840\u6813\u6027\u75c5\u5909\u306e\u753b\u50cf\u8a3a\u65ad\u3011 \u5fc3\u81d3\u3000\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306b\u304a\u3051\u308b\u51a0\u52d5\u8108\u75c5\u5909\u306e\u753b\u50cf\u8a3a\u65ad. \u8840\u6813\u3068\u5faa 15: 244-248, 2007
\n23. \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u4e09\u6728\u3000\u5747, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u8c9e\u672c\u548c\u5f66. 3.0T\u3067\u306e\u8133\u704c\u6d41MRI. \u65ad\u5c64\u6620\u50cf\u7814\u7a76\u4f1a\u96d1\u8a8c 34: 24-29, 2007
\n24. \u6771\u91ce \u535a, \u57ce\u6238\u8f1d\u4ec1, \u83c5\u539f\u656c\u6587, \u671b\u6708\u8f1d\u4e00, \u9f4b\u85e4 \u5b9f, \u5009\u7530 \u8056, \u5ca1\u5c71\u82f1\u6a39, \u6a9c\u57a3\u5be6\u7537. \u51a0\u52d5\u8108\u306e\u5f62\u614b\u30fb\u6a5f\u80fd\u306e\u540c\u6642\u89e3\u6790. \u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66 8: 41-43, 2007
\n25. \u6771\u91ce \u535a, \u9f4b\u85e4 \u5b9f, \u4e95\u4e0a \u7950\u99ac, \u5ca1\u5c71 \u82f1\u6a39, \u6a9c\u57a3 \u5be6\u7537, \u4e09\u6728 \u5747, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b \u5fd7\u6d25\u6c5f, \u6c5f\u539f \u79c0\u5b9f, \u8c9e\u672c \u548c\u5f66. 3T MRI\u306e\u81e8\u5e8a \u5fc3. \u81e8\u5e8a\u753b\u50cf 23: 1282-1292, 2007
\n26. \u671b\u6708\u8f1d\u4e00. \u4e3b\u8981\u75be\u60a3\u306e\u4ee3\u8868\u7684CT,MRI\u50cf\u3000\u521d\u671f\u7814\u4fee\u306e\u6642\u306b\u8eab\u306b\u3064\u3051\u3066\u304a\u304f\u3079\u304d\u5178\u578b\u50cf\u306e\u30dd\u30a4\u30f3\u30c8\u3000\u5fc3\u81d3\u30fb\u5927\u8840\u7ba1\u3000\u9032\u6b69\u3059\u308b3\u6b21\u5143CT\u3000\u5fc3\u30ab\u30c6\u3092\u3057\u306a\u304f\u3066\u3082\u51a0\u52d5\u8108\u304c\u898b\u3048\u308b. \u81e8\u5e8a\u7814\u4fee\u30d7\u30e9\u30af\u30c6\u30a3\u30b9 4: 24-29, 2007
\n27. \u5e73\u7530\u96c5\u662d, \u6d25\u7530\u5b5d\u6cbb, \u5175\u982d\u670b\u5b50, \u6751\u4e0a\u6b63\u54f2, \u671b\u6708\u8f1d\u4e00. 16\u5217MDCT\u3092\u7528\u3044\u305f\u30ac\u30b9\u30c8\u30ed\u30b0\u30e9\u30d5\u30a3\u30f3\u9020\u5f71CT\u306b\u3088\u308b\u5c0f\u8178\u75be\u60a3\u306e\u8a55\u4fa1. \u81e8\u5e8a\u653e\u5c04\u7dda 52: 891-897, 2007
\n\u25a0<\/span> \u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868<\/strong>
\n<\/a>\u25cf<\/span> \u56fd\u969b\u5b66\u4f1a
\n28. Yasushi Hamamoto, Masaaki Kataoka. Target selection in multiple spinal metastases. 25th European Society for Therapeutic Radiation Oncology (2006. 10, Leipzig)
\n29. Miyazaki S, Murase K, Yang X, Sugawara Y, Kajihara M, Sakayama K, Kikuchi K, Mochizuki T. Development of a visualization method for assessing treatment response in tumors using dynamic contrast-enhanced magnetic resonance imaging. The International Society for Optical Engineering (SPIE) Medical Imaging (2007. 2, San Diego)
\n30. M. Y. Ikura, S. Ohsumi, T. Mochizuki, S. Takashima. Variation of apparent diffusion coefficient values of normal mammary gland in menstrual cycle using diffusion-weighted magnetic resonance imaging. ECR2007 (2007. 3, Vienna)
\n31. T.Hyodo, T. Tsuda, M. Hirata, H. Tanaka, T. Mochizuki. Portal veins of the caudate lobe: Demonstration by three-dimensional CT during arterial portography using integrated 16 channel MDCT\/angio system. ECR2007 (2007. 3, Vienna)
\n32. T. Tsuda, T.Hyodo, M. Hirata, T. Mochizuki. Intravenous three-dimensional CT portography assisted by saline flush technique in patients with liver cirrhosis. ECR2007 (2007. 3, Vienna)
\n33. M. Hirata, T. Hyodo, T. Tsuda, T. Mochizuki. What is the advantage of angio-CT system equipped with 16-channel MDCT?: Detection of feeding artery during transcatheter arterial chemoembolization for hepatocellular carcinomas using 3D-CT angiography generated from the data set of CT hepatic arteriography. ECR2007 (2007. 3, Vienna)
\n34. Y. Hiratsuka, H. Miki, K. Kikuchi, I. Kiriyama, T. Mochizuki, S. Takahashi, I. Matsubara, and K. Sadamoto. Evaluation of Anterior Choroidal Artery on 3T 3D TOF MRA. 15th ISMRM (2007. 5, Berlin)
\n35. Y. Hiratsuka, H. Miki, K. Kikuchi, I. Kiriyama, T. Mochizuki, S. Takahashi, I. Matsubara, and K. Sadamoto. Evaluation of Intracranial Aneurysms with 3T TOF MRA: Compared to 64-MDCTA. 15th ISMRM (2007. 5, Berlin)
\n36. Nagao M, Uemura M, Tokunaga N, Higashino H, Mochizuki T, Murase K. Detection of myocardial ischemia using contrast-enhanced 64-slice MDCT: comparison with stress\/rest myocardial scintigraphy. 54th \u7c73\u56fd\u6838\u533b\u5b66\u5b66\u4f1a (2007. 6, Washington)
\n37. Miyazaki S, Murase K, Sugawara Y, Kajihara M, Kikuchi K, Miki H, Mochizuki T. A visualization method for assessment of treatment response in tumors using dynamic contrast-enhanced magnetic resonance imaging. CARS (2007. 6, Berlin)
\n38. Takahashi Y, Mochizuki T, Murase K, Higashino H, Sugawara Y, Kinda A. Usefulness of the limited-area backprojection reconstruction method in the 360 degrees acquisition for myocardial SPECT. CARS (2007. 6, Berlin)
\n39. M. Hirata, H. Tanaka, T. Hyodo, T. Murakami, T. Tsuda, T. Mochizuki. Detection of feeding artery of hepatocellular carcinoma using 3D-CT angiography with combined angiography 16 channel MDCT system, compared with conventional DSA. the Annual Meeting and Postgraduate Course of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE 2007) (2007. 9, Athens, Greece)
\n40. M. Mitsumori, M Kataoka, et al. Outcome of Radiation Therapy for Brain Metasases From Breast Cancer: A Multi-Center Experience in the Era of Trastuzumab. 49th ASTRO (2007. 10, Loss Angeles)
\n41. Yasushi Hamamoto, Masaaki Kataoka, Hhirobumi Honda. Pitfalls of definition of internal target volume using long-time scan CT. 49th American Society for Therapeutic Radiation Oncology (2007. 10, Los Angeles)
\n42. Miki H, Hiratsuka Y, Kiriyama I, Kikuchi K, Mochizuki T, Takahashi S, Matsubara I, Sadamoto K. 3-T TOF MR Angiography in Intracranial Aneurysms: Clinical Protocol and Limitation. 20th \u56fd\u969bMRA\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7 (2007. 10, Istanbul)
\n43. Miyazaki S, Murase K, Sugawara Y, Kikuchi K, Mochizuki T, Sakayama K. Development of a visualization method for assessing treatment response in tumors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). 93th RSNA (2007. 11, Chicago)
\n44. M Hirata, T Tsuda, H Tanaka, Mochizuki, M Murakami, T Hyodo, MD. The advantage of angio-CT system equipped with 16-channel MDCT. Detection of feeding artery during transcatheter arterial chemoembolisation for hepatocellular carcinomas using 3D-CT angiography generated from the data set of CT hepatic arteriography. 93th RSNA (2007. 11, Chicago)
\n45. T Hyodo, T Tsuda, M Hirata, M Murakami, T Mochizuki. Portal branches in the caudate lobe of the liver: demonstration by three-dimensional CT during arterial portography. 93th RSNA (2007. 11, Chicago)
\n46. Nagao M, Uemura M, Tokunaga N, Higashino H, Mochizuki T, Murase K. Detection of myocardial ischemia using contrast-enhanced 64-slice MDCT: comparison with stress\/rest myocardial scintigraphy. 93th \u5317\u7c73\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 11, Chicago)
\n47. Nagao M, Uemura M, Tokunaga N, Higashino H, Mochizuki T, Murase K. Quantification of Myocardial Perfusion by Contrast-enhanced 64-slice MDCT: Characterization Ischemic Myocardium. 93th \u5317\u7c73\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 11, Chicago)
\n48. Nagao M, Uemura M, Tokunaga N, Higashino H, Mochizuki T, Murase K. Comparison of late enhancement MR imaging and 99mTc-pyrophosphate scintigraphy in reperfused acute myocardial infarction. 93th \u5317\u7c73\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 11, Chicago)
\n49. M. Y. Ikura, H. Ikura, K. Shimizu, T. Mochizuki, H. Ebara, T Nagareda, Y. Imai. Optimization of Detector Size for Observation of the Peripheral Lung Using Synchrotron Radiation CT. 12th APSR2007 (2007. 12, Australia)
\n<\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09
\n50. \u4e09\u6728\u3000\u5747, \u5e73\ufa10\u7fa9\u5eb7, \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u677e\u539f\u4e00\u90ce, \u8c9e\u672c\u548c\u5f66. Volume Rendering\u6cd5\u3092\u7528\u3044\u305f3T-TOF MRA\u306e\u524d\u8108\u7d61\u53e2\u52d5\u8108\u306e\u63cf\u51fa\u80fd\u306e\u691c\u8a0e\uff1a64\u5217MDCTA\u306e\u6bd4\u8f03. \u7b2c12\u56de 3\u6b21\u5143CT\u30fbMRI\u7814\u7a76\u4f1a (2007. 2, \u9ad8\u677e)
\n51. \u6850\u5c71\u90c1\u5b50, \u4e09\u6728\u3000\u5747, \u5e73\u585a\u7fa9\u5eb7, \u83ca\u6c60\u6075\u4e00, \u671b\u6708\u8f1d\u4e00. \u9ad8\u5206\u89e3\u80fd\u4e09\u6b21\u5143MRI\u306b\u3088\u308b\u4e0b\u982d\u9802\u5c0f\u8449\u306e\u8133\u8868\u89e3\u5256\u89e3\u6790. \u7b2c36\u56de \u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 2, \u9ad8\u677e)
\n52. \u5e73\u585a\u3000\u7fa9\u5eb7, \u4e09\u6728\u3000\u5747, \u83ca\u6c60\u3000\u6075\u4e00, \u671b\u6708\u3000\u8f1d\u4e00, \u9ad8\u6a4b\u3000\u5fd7\u6d25\u6c5f, \u8c9e\u672c\u3000\u548c\u5f66. Volume Rendering\u753b\u50cf\u3092\u7528\u3044\u305f3tesla 3D TOF MRA\u306864\u5217MDCTA\u306e\u6bd4\u8f03\uff1a\u8133\u52d5\u8108\u7624\u5468\u56f2\u5c0f\u8840\u7ba1\u306e\u63cf\u51fa\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c36\u56de \u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 2, \u9ad8\u677e)
\n53. \u83ca\u6c60\u6075\u4e00. \u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff1a3T MRI\u306e\u81e8\u5e8a\uff1a\u73fe\u72b6\u3068\u5c06\u6765\u5c55\u671b\u30003.PWI. \u7b2c36\u56de \u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 2, \u9ad8\u677e)
\n54. Hiroshi Higashino, Makoto Saito, Akira Kurata, Hideki Okayama, Jitsuo Higaki, Teruhito Kido, Teruhito Mochizuki, Kazuhiko Ishikawa, Kazuhiko Sadamoto. Advantages of 3.0T MRI Cardiac Imaging. \u7b2c71\u56de Annual Scientific Meeting of the Japanese Circulation Society (2007. 3, \u795e\u6238)
\n55. Hiroshi Higashino, Akira Kurata, Hideki Okayama, Jitsuo Higaki, Teruhito Kido, Teruhito Mochizuki, Shuji Tanada. Cardiac Functional Analysis with “One-beat Whole Heart Imaging” Using the 2nd Spec 256-MSCT. \u7b2c71\u56de Annual Scientific Meeting of the Japanese Circulation Society (2007. 3, \u795e\u6238)
\n56. Nagao M, Uemura M, Tokunaga N, Higashino H, Mochizuki T, Murase K. Chracterization of myocardial perfusion in hypertrophic cardiomyopathy assessed by 64-slice MDCT angiography. \u7b2c71\u56de \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a (2007. 3, \u795e\u6238)
\n57. \u6771\u91ce\u535a. \u30e9\u30a6\u30f3\u30c9\u30c6\u30fc\u30d6\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f38 \u5fc3\u7b4bviability\u306e\u8a55\u4fa1\u6cd5. \u7b2c71\u56de \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u96c6\u4f1a (2007. 3, \u795e\u6238)
\n58. \u7af9\u53e3\u5d07, \u9ad8\u5c71\u535a\u6a39, \u4e95\u4e0a\u7950\u99ac, \u7af9\u5185\u76f4\u5b50, \u66fd\u6211\u90e8\u4e00\u90ce, \u83c5\u539f\u656c\u6587. \u8179\u90e8\u920d\u7684\u5916\u50b7\u306b\u304a\u3051\u308b\u8178\u7ba1\u53ca\u3073\u8178\u9593\u819c\u640d\u50b7\u306eCT\u6240\u898b. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n59. \u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e. \u2161\uff5e\u2163A\u671f\u80f8\u90e8\u98df\u9053\u6241\u5e73\u4e0a\u76ae\u764c\u306e\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u306b\u3088\u308b\u6cbb\u7642\u6210\u7e3e. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2007. 4, \u6a2a\u6d5c)
\n60. \u9577\u5c3e\u5145\u5c55, \u4e0a\u6751\u96c5\u5f66, \u5fb3\u6c38\u4f38\u5b50, \u6771\u91ce\u535a, \u671b\u6708\u8f1d\u4e00, \u6751\u702c\u7814\u4e5f, \u4e80\u7530\u7950\u5b50. Assessment of myocardial pefusion on ischemic myocardium by coronary MDCT angiography. \u7b2c66\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 4, \u6a2a\u6d5c)
\n61. \u5c45\u5009\u535a\u5f66(\u6e21\u90e8\u5185\u79d1 \u653e), \u6e05\u6c34\u5065\u6cbb, \u6c5f\u539f\u79c0\u7f8e, \u671b\u6708\u8f1d\u4e00, \u6d41\u7530\u667a\u6587. Micro-CT\u3092\u7528\u3044\u305f\u672b\u68a2\u80ba\u306e\u5f62\u614b\u5b66\u7684\u53ca\u3073\u75c5\u614b\u751f\u7406\u5b66\u7684\u8a55\u4fa1(Morphologic and Pathophysiologic Evaluation of the Peripheral Lung Using Micro-CT)(. \u7b2c66\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a (2007. 4, \u6a2a\u6d5c)
\n62. \u5bae\u5d0e\u5c06\u5e73, \u6751\u702c\u7814\u4e5f, \u83c5\u539f\u656c\u6587, \u694a\u6681\u6885, \u671b\u6708\u8f1d\u4e00. Dynamic MRI\u3092\u7528\u3044\u305f\u816b\u760d\u306e\u6cbb\u7642\u52b9\u679c\u5224\u5b9a\u306b\u304a\u3051\u308b\u8996\u899a\u7684\u8a55\u4fa1\u6cd5\u306e\u958b\u767a. \u7b2c63\u56de \u65e5\u672c\u533b\u5b66\u7269\u7406\u5b66\u4f1a (2007. 4, \u6a2a\u6d5c)
\n63. \u5ca9\u6751\u5353\u660e,\u5bae\u5ddd\u6b63\u7537,\u77f3\u4e38\u826f\u5f18,\u67cf\u539f\u8ce2\u4e00,\u4e2d\u6751\u8aa0\u6cbb,\u83ca\u6c60\u9686\u5fb3,\u5ddd\u4e2d\u5d07,\u5c0f\u4e80\u96c5\u5e83. \u80ba\u764cN\u56e0\u5b50\u306e\u8a3a\u65ad\u306b\u304a\u3051\u308b\u9ad8\u5206\u89e3\u80fdPET\/CT\u306e\u6709\u7528\u6027. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n64. \u6d25\u7530\u5b5d\u6cbb(\u611b\u5a9b\u5927\u5b66 \u653e), \u68b6\u539f\u670b\u5b50, \u5e73\u7530\u96c5\u662d, \u6751\u4e0a\u6b63\u54f2, \u4e09\u6728\u5747, \u671b\u6708\u8f1d\u4e00. \u809d\u786c\u5909\u60a3\u8005\u306b\u304a\u3051\u308b\u7d4c\u9759\u8108\u60273\u6b21\u5143CT\u9580\u8108\u9020\u5f71\u3067\u306e, \u751f\u98df\u30d5\u30e9\u30c3\u30b7\u30e5\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n65. \u68b6\u539f\u670b\u5b50(\u611b\u5a9b\u5927\u5b66 \u653e), \u6d25\u7530\u5b5d\u6cbb, \u5e73\u7530\u96c5\u662d, \u6751\u4e0a\u6b63\u54f2, \u671b\u6708\u8f1d\u4e00. 3D-CTAP\u3067\u307f\u308b\u9580\u8108\u306e\u5c3e\u72b6\u8449\u679d. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n66. \u5e73\u7530 \u96c5\u662d, \u6d25\u7530 \u5b5d\u6cbb, \u68b6\u539f \u670b\u5b50, \u6751\u4e0a \u6b63\u54f2, \u7530\u4e2d \u5b8f\u660e, \u671b\u6708 \u8f1d\u4e00 . 16\u5217MDCT\u3092\u642d\u8f09\u3057\u305fAngio-CT\u30b7\u30b9\u30c6\u30e0\u306e\u81e8\u5e8a\u5fdc\u7528 -CTHA\u306b\u3088\u308bHCC\u6804\u990a\u8840\u7ba1\u306e\u540c\u5b9a- . \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n67. \u4e95\u624b\u9999\u5948(\u611b\u5a9b\u5927\u5b66 \u653e), \u6751\u4e0a\u5fe0\u53f8, \u6771\u91ce\u535a, \u7530\u982d\u88d5\u4e4b, \u8352\u5ddd\u61b2\u4e8c, \u671b\u6708\u8f1d\u4e00. 2-shot dual-energy subtraction\u6cd5\u306b\u304a\u3051\u308bmisregistration\u306e\u8efd\u6e1b\u3078\u306e\u8a66\u307f\u3000\u5fc3\u96fb\u540c\u671f\u3092\u7528\u3044\u3066. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n68. \u6771\u91ce \u535a, \u57ce\u6238 \u8f1d\u4ec1, \u4e95\u624b \u9999\u5948, \u6751\u4e0a \u5fe0\u53f8, \u6d25\u7530 \u5b5d\u6cbb, \u4e09\u6728 \u5747, \u671b\u6708 \u8f1d\u4e00. Virtual Cardioscopy Using ECG-gated Multi-slice Computed Tomography. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n69. \u6771\u91ce \u535a, \u57ce\u6238 \u8f1d\u4ec1, \u4e95\u624b \u9999\u5948, \u6751\u4e0a \u5fe0\u53f8, \u4e09\u6728 \u5747, \u671b\u6708 \u8f1d\u4e00, \u9ad8\u6a4b \u5fd7\u6d25\u6c5f, \u6751\u702c \u7814\u4e5f. Cardiac MR Imaging at 3T. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n70. \u4e2d\u6751\u8aa0\u6cbb,\u5bae\u5ddd\u6b63\u7537,\u83ca\u6c60\u9686\u5fb3,\u77f3\u4e38\u826f\u5f18,\u5ddd\u4e2d\u5d07,\u5ca9\u6751\u5353\u660e,\u5c0f\u4e80\u96c5\u5e83,\u67cf\u539f\u8ce2\u4e00,\u671b\u6708\u8f1d\u4e00. \u8133\u816b\u760d\u03b3-knife\u6cbb\u7642\u5f8c\u306e\u518d\u767a\u8a3a\u65ad\u306b\u304a\u3051\u308bC-11 Methionin\/F-18 FDG PET\/CT\u4e00\u65e5\u6cd5\u306e\u6709\u7528\u6027. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n71. \u5e73\ufa10\u7fa9\u5eb7, \u4e09\u6728\u3000\u5747, \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u677e\u539f\u4e00\u90ce, \u8c9e\u672c\u548c\u5f66. Volume Rendering\u753b\u50cf\u3092\u7528\u3044\u305f\u8133\u52d5\u8108\u7624\u306e\u5f62\u72b6\u8a55\u4fa1\uff1a3 tesla TOF MRA\u306864\u5217MDCTA\u306e\u6bd4\u8f03. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n72. \u718a\u91ce\u6b63\u58eb, \u5ca1\u7530\u771f\u5e83, \u8db3\u5229\u7adc\u4e00\u6717, \u7d30\u91ce\u771e, \u6751\u4e0a\u5353\u901a, \u5e73\u7530\u96c5\u662d, \u6d25\u7530\u5b5d\u6cbb, \u83ca\u6c60\u6075\u4e00, \u4e09\u6728\u5747, \u671b\u6708\u8f1d\u4e00. \u30d5\u30a7\u30eb\u30ab\u30eb\u30dc\u30c8\u30e9\u30f3\u9020\u5f71MRI\u306b\u304a\u3051\u308bT1\u5f37\u8abf\u50cf\u64ae\u5f71\u30bf\u30a4\u30df\u30f3\u30b0\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n73. \u9ad8\u6a4b\u5fe0\u7ae0, \u8d64\u5b97\u660e\u4e45, \u6700\u4e0a\u535a. \u5727\u8feb\u9aa8\u6298\u306e\u8a3a\u65ad\u306b\u304a\u3051\u308b\u62e1\u6563\u5f37\u8abf\u753b\u50cf\u306e\u6709\u7528\u6027\uff1a\u826f\u6027\u304a\u3088\u3073\u75c5\u7684\u9aa8\u6298\u306e\u9451\u5225\u306b\u3064\u3044\u3066. \u7b2c66\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2007. 4, \u6a2a\u6d5c)
\n74. \u5e73\u585a\u7fa9\u5eb7, \u4e09\u6728\u3000\u5747, \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u677e\u539f\u4e00\u90ce, \u8c9e\u672c\u548c\u5f66. \uff13tesla 3D TOF MRA\u306b\u304a\u3051\u308b\u524d\u8108\u7d61\u53e2\u52d5\u8108\u306e\u63cf\u51fa\u80fd\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c15\u56de \u65e5\u672cMRA\u7814\u7a76\u4f1a (2007. 6, \u798f\u5ca1)
\n75. \u4e09\u6728\u3000\u5747. 3T MRI\u306b\u3088\u308b\u8133\u8840\u7ba1\u75c5\u5909\u306e\u8a55\u4fa1 [\u8133\u52d5\u8108\u7624\u306e3T MRA]. \u7b2c15\u56de \u65e5\u672cMRA\u7814\u7a76\u4f1a (2007. 6, \u798f\u5ca1)
\n76. \u5bae\u5ddd\u6b63\u7537. \u7b2c8\u56de\u5b66\u4f1a\u8cde\u53d7\u8cde\u8b1b\u6f14\u3000\u5fc3\u81d3\u306e\u5206\u5b50\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\uff1a\u85ac\u5264\u8ca0\u8377\u6cd5\u304b\u3089PET\u306b\u3088\u308b\u907a\u4f1d\u5b50\u767a\u73fe\u306e\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u307e\u3067. \u7b2c17\u56de \u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a (2007. 6, \u6771\u4eac)
\n77. \u65b0\u90e8\u3000\u8b72, \u7247\u5ca1\u6b63\u660e, \u4ed6. \u8179\u90e8\u508d\u5927\u52d5\u8108\u30ea\u30f3\u30d1\u7bc0\u306e\u307f\u306e\u518d\u767a\u5b50\u5bae\u9838\u764c\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u591a\u65bd\u8a2d\u5171\u540c\u9061\u53ca\u7684\u7814\u7a76. \u7b2c42\u56de \u65e5\u672c\u5a66\u4eba\u79d1\u816b\u760d\u5b66\u4f1a (2007. 6, \u6771\u4eac)
\n78. \u6b66\u667a\u3000\u6075, \u5175\u982d\u670b\u5b50, \u6d25\u7530\u5b5d\u6cbb, \u5e73\u7530\u96c5\u662d, \u6751\u4e0a\u6b63\u54f2, \u5c71\u672c\u7950\u53f8, \u6e21\u90e8\u7950\u53f8, \u6b66\u7530\u82f1\u6a39. \u7c98\u6db2\u7523\u751f\u306e\u8457\u540d\u306a\u809d\u5185\u56a2\u80de\u6027\u80c6\u7ba1\u816b\u760d\u306e\u4e00\u4f8b. \u7b2c21\u56de \u8179\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a (2007. 6, \u5bae\u5d0e)
\n79. \u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e. Long-time Scan CT\u306b\u3088\u308bInternal Target Volume\u306e\u7cbe\u5ea6\u3092\u640d\u306d\u308b\u56e0\u5b50. \u7b2c16\u56de \u65e5\u672c\u9ad8\u7cbe\u5ea6\u5916\u90e8\u7167\u5c04\u7814\u7a76\u4f1a (2007. 7, \u6771\u4eac)
\n80. \u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e. \u5f53\u9662\u306b\u304a\u3051\u308b\u4e73\u764c\u8133\u8ee2\u79fb\u75c7\u4f8b\u306e\u653e\u5c04\u7dda\u6cbb\u7642\u6210\u7e3e. \u7b2c16\u56de \u65e5\u672c\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u5b66\u4f1a (2007. 7, \u6771\u4eac)
\n81. \u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e. \u540c\u6642\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u3092\u65bd\u884c\u3057\u305fIII\uff0cIV\u671f\u4e2d\u30fb\u4e0b\u54bd\u982d\u764c\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c20\u56de \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a (2007. 7, \u6771\u4eac)
\n82. \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056, \u4e95\u4e0a\u7950\u99ac, \u6771\u91ce\u535a, \u9f4b\u85e4\u5b9f, \u5ca1\u5c71\u82f1\u6a39, \u6867\u57a3\u5be6\u7537, \u6751\u702c\u7814\u4e5f, \u671b\u6708\u8f1d\u4e00. MDCT\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u8840\u6d41\u8a55\u4fa1\u306e\u53ef\u80fd\u6027. \u7b2c65\u56de \u5fc3\u81d3\u8840\u7ba1\u7814\u7a76\u4f1a (2007. 7, \u4ed9\u53f0)
\n83. \u4e95\u4e0a\u7950\u99ac, \u9f4b\u85e4\u5b9f, \u57ce\u6238\u8f1d\u4ec1, \u694a\u6681\u6885, \u5009\u7530\u8056, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u672c\u7530\u4fca\u7537, \u5ca1\u5c71\u82f1\u6a39, \u6771\u91ce\u535a, \u8c9e\u672c\u548c\u5f66, \u6751\u702c\u7814\u4e5f, \u6867\u57a3\u5be6\u7537, \u671b\u6708\u8f1d\u4e00. 3.0T MRI\u3092\u7528\u3044\u305fCine-tagging MRI\u306b\u3088\u308b\u5de6\u5ba4\u58c1\u904b\u52d5\u306e\u5b9a\u91cf\u89e3\u6790\u306e\u8a66\u307f. \u7b2c65\u56de \u5fc3\u81d3\u8840\u7ba1\u7814\u7a76\u4f1a (2007. 7, \u4ed9\u53f0)
\n84. \u83ca\u6c60\u9686\u5fb3, \u4e2d\u6751\u8aa0\u6cbb, \u97f3\u898b\u66a2\u4e00, \u5c0f\u4e80\u96c5\u5e83, \u68b6\u539f\u3000\u8aa0, \u677e\u672c\u5f18\u91cf, \u66fd\u6211\u90e8\u4e00\u90ce, \u77f3\u4e38\u826f\u5e83, \u5bae\u5ddd\u6b63\u7537. FDG-PET\u304c\u5927\u52d5\u8108\u58c1\u306e\u708e\u75c7\u3092\u793a\u3057\u3066\u3044\u305f\u3068\u601d\u308f\u308c\u308b\u4e00\u4f8b. \u7b2c\u56de \u6838\u533b\u5b66\u75c7\u4f8b\u691c\u8a0e\u4f1a (2007. 8, \u5927\u962a)
\n85. \u77f3\u4e38\u3000\u826f\u5e83\uff0c\u97f3\u898b\u3000\u66a2\u4e00\uff0c\u5c0f\u4e80\u3000\u96c5\u5e83\uff0c\u68b6\u539f\u3000\u8aa0\uff0c\u66fd\u6211\u90e8\u3000\u4e00\u90ce\uff0c\u677e\u6728\u3000\u5f15\u91cf\uff0c\u83ca\u6c60\u3000\u9686\u5fb3\uff0c\u4e2d\u6751\u3000\u8aa0\u6cbb\uff0c\u5bae\u5ddd\u3000\u6b63\u7537\uff0c\u67cf\u539f\u3000\u8ce2\u4e00. \u900f\u6790\u30b7\u30e3\u30f3\u30c8PTA\u65bd\u884c\u524d\u306e\u9020\u5f71\uff13D MRA\u306e\u6709\u7528\u6027. \u7b2c35\u56de \u65e5\u672c\u6838\u78c1\u6c17\u5171\u9cf4\u5b66\u4f1a (2007. 9, \u795e\u6238)
\n86. \u5e73\u585a\u7fa9\u5eb7, \u4e09\u6728\u5747, \u83ca\u6c60\u6075\u4e00, \u6850\u5c71\u90c1\u5b50, \u671b\u6708\u8f1d\u4e00, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u8c9e\u672c\u548c\u5f66. \u672a\u7834\u88c2\u8133\u52d5\u8108\u7624\u306e\u8853\u524d\u8a55\u4fa1\u306b\u304a\u3051\u308b3\u30c6\u30b9\u30e93D TOF MRA\u306e\u6709\u7528\u6027\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c35\u56de \u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2007. 9, \u795e\u6238)
\n87. \u6850\u5c71\u90c1\u5b50, \u83ca\u6c60\u6075\u4e00, \u671b\u6708\u8f1d\u4e00, \u5e73\u585a\u7fa9\u5eb7, \u4e09\u6728\u5747, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u677e\u539f\u4e00\u90ce, \u8c9e\u672c\u548c\u5f66. 3T-PWI\u306b\u304a\u3051\u308b\u5c40\u6240\u8133\u8840\u6d41\u91cf\u306e\u8a55\u4fa1\uff1aSE-EPI\u3068GRE-EPI\u3068\u306e\u6bd4\u8f03. \u7b2c35\u56de \u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2007. 9, \u795e\u6238)
\n88. \u5ca1\u7530\u6643\u6cbb, \u76f8\u99ac\u3000\u52aa, \u6a29\u85e4\u5c1a\u5f66, \u694a\u3000\u6681\u6885, \u5c71\u5d5c\u6d0b\u4e00, \u83ca\u6c60\u6075\u4e00, \u4e09\u6728\u3000\u5747, \u671b\u6708\u8f1d\u4e00, \u77f3\u4e95\u4e00\u6210, \u6751\u702c\u7814\u4e5f. MRI\u3092\u7528\u3044\u305f\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u306e\u8a3a\u65ad\u652f\u63f4\u30b7\u30b9\u30c6\u30e0\u306e\u958b\u767a. \u7b2c35\u56de \u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2007. 9, \u795e\u6238)
\n89. \u4e95\u4e0a\u7950\u99ac, \u6771\u91ce\u535a, \u4e09\u6728\u5747, \u671b\u6708\u8f1d\u4e00, \u9f4b\u85e4\u5b9f, \u5ca1\u5c71\u82f1\u6a39, \u6a9c\u57a3\u5be6\u7537, \u694a\u3000\u6681\u6885, \u6751\u702c\u4ef6\u4e5f, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u672c\u7530\u4fca\u7537, \u8c9e\u672c\u548c\u5f66. 3.0T CINE-tagging MRI\u306b\u3088\u308b\u9673\u65e7\u6027\u5fc3\u7b4b\u6897\u585e\u75c7\u4f8b\u306b\u304a\u3051\u308b\u5de6\u5ba4\u58c1\u904b\u52d5\u306e\u5b9a\u91cf\u8a55\u4fa1. \u7b2c35\u56de \u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2007. 9, \u795e\u6238)
\n90. \u6771\u91ce\u535a, \u4e95\u4e0a\u7950\u99ac, \u85e4\u5b9f, \u5ca1\u5c71\u82f1\u6a39, \u6a9c\u57a3\u5be6\u7537, \u4e09\u6728\u5747, \u671b\u6708\u8f1d\u4e00, \u6751\u702c\u4ef6\u4e5f, \u9ad8\u6a4b\u5fd7\u6d25\u6c5f, \u6c5f\u539f\u79c0\u5b9f, \u8c9e\u672c\u548c\u5f66. \u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff1a\u9ad8\u78c1\u5834MRI, \u5fc3\u81d3\u306e3T MRI. \u7b2c35\u56de \u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2007. 9, \u795e\u6238)
\n91. \u83ca\u6c60\u9686\u5fb3,\u5bae\u5ddd\u6b63\u7537,\u4e2d\u6751\u8aa0\u6cbb,\u97f3\u898b\u66a2\u4e00,\u5c0f\u4e80\u96c5\u5e83,\u68b6\u539f\u8aa0,\u66fd\u6211\u90e8\u4e00\u90ce,\u77f3\u4e38\u826f\u5f18,\u67cf\u539f\u8ce2\u4e00. FDG\u8133PET\u306b\u304a\u3051\u308b3D\u53ce\u96c6\u30682D\u53ce\u96c6\u306e\u753b\u50cf\u306e\u5dee\u7570\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c47\u56de \u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a (2007. 11, \u4ed9\u53f0)
\n92. \u83ca\u6c60\u9686\u5fb3,\u5bae\u5ddd\u6b63\u7537,\u4e2d\u6751\u8aa0\u6cbb,\u97f3\u898b\u66a2\u4e00,\u5c0f\u4e80\u96c5\u5e83,\u68b6\u539f\u8aa0,\u66fd\u6211\u90e8\u4e00\u90ce,\u77f3\u4e38\u826f\u5f18,\u67cf\u539f\u8ce2\u4e00. \u30e1\u30c1\u30aa\u30cb\u30f3\u8133\u816b\u760dPET\u306e3D\u53ce\u96c6\u6761\u4ef6\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c47\u56de \u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a (2007. 11, \u4ed9\u53f0)
\n93. \u6771\u91ce\u535a. \u30de\u30eb\u30c1\u30e2\u30c0\u30ea\u30c6\u30a3\u6642\u4ee3\u306b\u304a\u3051\u308b\u5fc3\u81d3\u6838\u533b\u5b66\u306e\u6b69\u3080\u3079\u304d\u9053 CT\u304a\u3088\u3073MRI\u306e\u767a\u5c55\u3068\u5fc3\u81d3\u6838\u533b\u5b66\u306e\u30b5\u30dd\u30fc\u30c8. \u7b2c47\u56de \u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a (2007. 11, \u4ed9\u53f0)
\n94. \u95a2\u53e3\u5efa\u6b21, \u7247\u5ca1\u6b63\u660e\u3000\u4ed6. \u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u304a\u3088\u3073NCCN\u306b\u3088\u308b\u4e73\u304c\u3093\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306e\u65e5\u7c73\u6bd4\u8f03. \u7b2c20\u56de \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a (2007. 12, \u798f\u5ca1)
\n95. \u7247\u5ca1\u6b63\u660e, \u6ff1\u672c\u3000\u6cf0, \u9152\u4e95\u4f38\u4e5f. \u524d\u7acb\u817a\u304c\u3093IMRT\u306b\u304a\u3051\u308b\u76f4\u8178\u58c1\u7dda\u91cf\u5236\u9650\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c20\u56de \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a (2007. 12, \u798f\u5ca1)
\n<\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09
\n96. \u5c0f\u4e80\u96c5\u5e83,\u5ca9\u6751\u5353\u660e,\u5ddd\u4e2d\u5d07,\u77f3\u4e38\u826f\u5f18,\u83ca\u6c60\u9686\u5fb3,\u4e2d\u6751\u8aa0\u6cbb,\u5bae\u5ddd\u6b63\u7537,\u67cf\u539f\u8ce2\u4e00. \u80ba\u52d5\u9759\u8108\u763b\u306b\u5bfe\u3057\u3066\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f\u4e00\u4f8b. \u7b2c2\u56de \u611b\u5a9bInterventional Radiology(IVR)\u7814\u7a76\u4f1a (2007. 3, \u677e\u5c71)
\n97. \u539f\u4e95\u5ddd\u8c4a\u7ae0, \u9ad8\u5c71\u535a\u6a39, \u7af9\u5185\u76f4\u5b50, \u7af9\u53e3\u3000\u5d07, \u83c5\u539f\u656c\u6587, \u4ed6. \u80c6\u56a2\u637b\u8ee2\u75c7\u306e\uff11\u4f8b. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n98. \u5c0f\u4e80\u96c5\u5e83, \u97f3\u898b\u66a2\u4e00, \u68b6\u539f\u3000\u8aa0, \u677e\u672c\u5f18\u91cf, \u66fd\u6211\u90e8\u4e00\u90ce, \u77f3\u4e38\u826f\u5e83, \u83ca\u6c60\u9686\u5fb3, \u4e2d\u6751\u8aa0\u6cbb, \u5bae\u5ddd\u6b63\u7537, \u67cf\u539f\u8ce2\u4e00. \u8853\u5f8c\uff19\u5e74\u7d4c\u904e\u3057\u3066\u591a\u767a\u809d\u8ee2\u79fb\u3092\u304d\u305f\u3057\u305f\u81b5solid and pseudopapillary tumor\u306e\uff11\u4f8b. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n99. \u97f3\u898b\u66a2\u4e00, \u77f3\u4e38\u826f\u5e83, \u5c0f\u4e80\u96c5\u5e83, \u68b6\u539f\u3000\u8aa0, \u66fd\u6211\u90e8\u4e00\u90ce, , \u83ca\u6c60\u9686\u5fb3, \u4e2d\u6751\u8aa0\u6cbb, \u5bae\u5ddd\u6b63\u7537, \u67cf\u539f\u8ce2\u4e00. \u62e1\u6563\u5f37\u8abf\u753b\u50cf\u3067\u306e\u524d\u7acb\u817a\u764c\u8a3a\u65ad\u80fd\u306e\u691c\u8a0e. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n100. \u85e4\u539f\u611b, \u5409\u5ca1\u771f\u4e8c, \u6751\u4e0a\u5fe0\u53f8, \u5e73\u7530\u96c5\u662d, \u5175\u982d\u670b\u5b50, \u4e95\u624b\u9999\u5948, \u671b\u6708\u8f1d\u4e00, \u4ed6. Fallo\uff54\u56db\u5fb4\u75c7\u6839\u6cbb\u8853\u5f8c18\u5e74\u3092\u7d4c\u904e\u3057\u3066\u5927\u91cf\u5580\u8840\u3092\u6765\u305f\u3057\u305f\u75c7\u4f8b. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n101. \u4e0a\u6d25\u5b5d\u592a\u90ce, \u57ce\u6238\u8f1d\u4ec1, \u4e95\u4e0a\u7950\u99ac, \u30ab\u30f3\u30b6\u30fb\u30ec\u30cd\u30fb\u30a8\u30d7\u30f3\u30b6, \u6771\u91ce\u3000\u535a, \u671b\u6708\u8f1d\u4e00. CT\u304c\u6709\u7528\u3067\u3042\u3063\u305f\u5fc3\u7b4b\u7dda\u7dad\u816b\u306e\u4e00\u4f8b. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n102. \u4e80\u7530\u7950\u5b50, \u9577\u5c3e\u5145\u5c55, \u4e0a\u6751\u96c5\u5f66, \u5fb3\u6c38\u4f38\u5b50, \u6771\u91ce\u3000\u535a, \u671b\u6708\u8f1d\u4e00. Detection of myocardial ischemia using 64-slice CE-MDCT: comparison with stress\/rest myocardial scintigraphy. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n103. \u5e73\u7530\u96c5\u662d, \u7530\u4e2d\u5b8f\u660e, \u5175\u982d\u670b\u5b50, \u6d25\u7530\u5b5d\u6cbb, \u6b66\u667a\u6075, \u6751\u4e0a\u6b63\u54f2, \u671b\u6708\u8f1d\u4e00. \u8840\u7ba1\u585e\u6813\u8853\u306b\u3066\u6b62\u8840\u3057\u3048\u305f\u809d\u7d30\u80de\u764c\u306e\u808b\u9aa8\u8ee2\u79fb\u7834\u88c2\u306e\u4e00\u4f8b. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n104. \u6ff1\u672c\u3000\u6cf0, \u7247\u5ca1\u6b63\u660e, \u5c0f\u7530\u5c1a\u543e, \u7d30\u5ddd\u6d69\u5e73, \u9752\u91ce\u7965\u53f8, \u9152\u4e95\u4f38\u4e5f, \u4e95\u4e0a\u6b66, \u83c5\u7530\u6210\u7d00. \u540c\u6642\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u3092\u65bd\u884c\u3057\u305fIII, IV\u671f\u4e2d\u30fb\u4e0b\u54bd\u982d\u764c\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n105. \u7530\u53e3\u5343\u8535, \u897f\u5ddd\u3000\u6566, \u8d8a\u667a\u8a89\u53f8, \u85e4\u4e95\u3000\u5d07, \u671b\u6708\u8f1d\u4e00. \u5f53\u79d1\u306b\u304a\u3051\u308bBulky NK\/T cell lymphoma\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n106. \u7247\u5ca1\u6b63\u660e, \u6ff1\u672c\u3000\u6cf0, \u7d30\u5ddd\u6d69\u5e73, \u5c0f\u7530\u5c1a\u543e, \u9752\u91ce\u7965\u53f8, \u9152\u4e95\u4f38\u4e5f, \u4e95\u4e0a\u6b66, \u83c5\u7530\u6210\u7d00. \u524d\u7acb\u817a\u764cIMRT\u306b\u3080\u3051\u3066\u306e\u76f4\u8178\u58c1\u7dda\u91cf\u306e\u691c\u8a0e. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n107. \u7a32\u6708\u5343\u5c0b, \u6850\u5c71\u90c1\u5b50, \u5e73\u585a\u7fa9\u5eb7, \u83ca\u6c60\u6075\u4e00, \u4e09\u6728\u3000\u5747, \u671b\u6708\u8f1d\u4e00. \u5074\u982d\u9aa8\u816b\u760d\u306e\uff13\u4f8b. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n108. \u7d30\u5ddd\u6d69\u5e73, \u4e95\u4e0a\u3000\u6b66, \u83c5\u7530\u6210\u7d00, \u9152\u4e95\u4f38\u4e5f, \u9752\u91ce\u7965\u53f8, \u5c0f\u7530\u5c1a\u543e, \u7247\u5ca1\u6b63\u660e. \u9032\u884c\u5927\u8178\u30fb\u76f4\u8178\u764c\u30ea\u30f3\u30d1\u7bc0\u8ee2\u79fb\u306ePET-C\uff34\u3067\u306e\u8996\u899a\u7684\u8a55\u4fa1\u306b\u3088\u308b\u8a3a\u65ad\u80fd. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n109. \u7d30\u5ddd\u6d69\u5e73, \u4e95\u4e0a\u3000\u6b66, \u83c5\u7530\u6210\u7d00, \u9152\u4e95\u4f38\u4e5f, \u9752\u91ce\u7965\u53f8, \u5c0f\u7530\u5c1a\u543e, \u7247\u5ca1\u6b63\u660e. \u624b\u8853\u75c7\u4f8b\u306b\u304a\u3051\u308b\u98df\u9053\u764c\u8853\u524dPET-CT\u8a3a\u65ad. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n110. \u4e95\u4e0a\u3000\u6b66, \u7d30\u5ddd\u6d69\u5e73, \u83c5\u7530\u6210\u7d00, \u9152\u4e95\u4f38\u4e5f, \u9752\u91ce\u7965\u53f8, \u5c0f\u7530\u5c1a\u543e, \u5c71\u4e0b\u3000\u6cf0\u5f18, \u7247\u5ca1\u6b63\u660e. \u539f\u767a\u6027\u80ba\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308bFDG-PET\/CT\u3092\u7528\u3044\u305f\u7e26\u9694\u30ea\u30f3\u30d1\u7bc0\u8ee2\u79fb\u8a3a\u65ad\uff0d\u8996\u899a\u7684\u8a55\u4fa1\u306e\u6709\u7528\u6027\uff0d. \u7b2c108\u56de \u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2007. 6, \u5ca1\u5c71)
\n111. \u57ce\u6238\u502b\u4e4b, \u9ad8\u5c71\u535a\u6a39, \u7af9\u5185\u76f4\u5b50, \u539f\u4e95\u5ddd\u8c4a\u7ae0, \u6751\u4e0a\u5fe0\u53f8, \u7af9\u53e3\u5d07, \u83c5\u539f\u656c\u6587. Alagille\u75c7\u5019\u7fa4\u306e1\u4f8b. \u7b2c109\u56de \u7b2c109\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n112. \u6ff1\u672c\u6cf0\uff0c\u7247\u5ca1\u6b63\u660e. \u5f53\u9662\u306b\u304a\u3051\u308b\u4e73\u764c\u8133\u8ee2\u79fb\u75c7\u4f8b\u306e\u653e\u5c04\u7dda\u6cbb\u7642\u6210\u7e3e. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n113. \u5c0f\u4e80\u96c5\u5e83,\u77f3\u4e38\u826f\u5f18,\u97f3\u898b\u66a2\u4e00,\u68b6\u539f\u8aa0,\u677e\u6728\u5f18\u91cf,\u66fd\u6211\u90e8\u4e00\u90ce,\u83ca\u6c60\u9686\u5fb3,\u4e2d\u6751\u8aa0\u6cbb,\u5bae\u5ddd\u6b63\u7537. Segmental arterial mediolysis\u3068\u8003\u3048\u3089\u308c\u305f\u4e00\u4f8b. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n114. \u97f3\u898b\u66a2\u4e00,\u68b6\u539f\u8aa0,\u83ca\u6c60\u9686\u5fb3,\u5c0f\u4e80\u96c5\u5e83,\u677e\u6728\u5f18\u91cf,\u66fd\u6211\u90e8\u4e00\u90ce,\u77f3\u4e38\u826f\u5f18,\u4e2d\u6751\u8aa0\u6cbb,\u5bae\u5ddd\u6b63\u7537. \u5f53\u9662\u306b\u304a\u3051\u308bPET\/CT\u30c9\u30c3\u30af\u306e\u521d\u671f\u7d4c\u9a13. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n115. \u4e0a\u6d25\u5b5d\u592a\u90ce, \u7a32\u6708\u5343\u5c0b, \u6850\u5c71\u90c1\u5b50, \u897f\u5ddd\u3000\u6566, \u8d8a\u667a\u8a89\u53f8, \u85e4\u4e95\u3000\u5d07, \u671b\u6708\u8f1d\u4e00. \u5f53\u9662\u306b\u304a\u3051\u308b\u8ee2\u79fb\u6027\u8133\u816b\u760d\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u6cbb\u7642\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n116. \u6b66\u667a\u3000\u6075, \u5409\u5ca1\u771f\u4e8c, \u6d66\u5cf6\u96c4\u4ecb, \u6751\u7530\u7e41\u5229, \u5c0f\u6797\u96c4\u4e00, \u7530\u4e2d\u826f\u61b2, \u7af9\u4e0b\u82f1\u6b21, \u5927\u91ce\u82b3\u656c, \u6e21\u8fba\u5d07\u592b, \u4e0a\u7532\u5eb7\u4e8c. \u81b5Solid pesudopapillay tumor\u306e\u4e00\u4f8b. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n117. \u6c34\u91ce\u6d0b\u8f14, \u4e95\u624b\u9999\u5948, \u7530\u53e3\u5343\u8535, \u5e73\u585a\u7fa9\u5eb7, \u5175\u982d\u670b\u5b50, \u4e09\u6728\u3000\u5747, \u671b\u6708\u8f1d\u4e00. \u53f3\u5fc3\u623f\u5185\u4f38\u5c55\u3092\u6765\u3057\u305f\u6d78\u6f64\u6027\u80f8\u817a\u816b\u306e\u4e00\u4f8b. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n118. \u6771\u91ce\u3000\u535a, \u677e\u672c\u76f4\u4e5f, \u7b20\u4e95\u7763\u96c4, \u5009\u7530\u3000\u8056, \u57ce\u6238\u8f1d\u4e00, \u4e95\u4e0a\u7950\u99ac, \u57ce\u6238\u502b\u4e4b, \u83ca\u6c60\u6075\u4e00, \u6d25\u7530\u5b5d\u6cbb, \u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3\u6838\u533b\u5b66\u8aad\u5f71\u88dc\u52a9\u30c4\u30fc\u30eb\u304c\u6709\u7528\u3067\u3042\u3063\u305f\u75c7\u4f8b\uff5e\u30ea\u30b9\u30af\u968e\u5c64\u5316\u306e\u91cd\u8981\u6027\uff5e. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n119. \u6d66\u5cf6\u96c4\u4ecb, \u6b66\u667a\u3000\u6075, \u5409\u5ca1\u771f\u4e8c, \u6751\u7530\u7e41\u5229, \u6709\u53cb\u3000\u5b8f. \u9032\u884c\u6c17\u53e3\u8154\u764c\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u6cbb\u7642\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n120. \u5c0f\u7530\u5c1a\u543e, \u4e95\u4e0a\u3000\u6b66, \u7d30\u5ddd\u6d69\u5e73, \u9152\u4e95\u4f38\u4e5f, \u9752\u91ce\u7965\u53f8, \u83c5\u7530\u6210\u7d00, \u4e95\u53e3\u6771\u90ce, \u8c37\u6c34\u6b63\u4eba, \u7058\u91ce\u6210\u4eba, \u6c60\u7530\u5b9c\u592e, \u90a3\u9808\u6df3\u4e00\u90ce, \u5800\u4f38\u4e00\u90ce, \u677e\u539f\u3000\u5bdb, \u4ec1\u79d1\u667a\u88d5, \u68ee\u8107\u654f\u548c, \u68b6\u539f\u731b\u53f2, \u7247\u5c71\u6df3\u90ce, \u5927\u9053\u771f\u5fd7, \u6b66\u667a\u4fca\u6cbb. \u81ea\u5df1\u514d\u75ab\u6027\u81b5\u708e\uff12\u75c7\u4f8b\u306b\u304a\u3051\u308bFDG-PET\u306e\u6240\u898b. \u7b2c109\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71)
\n<\/a>\u25a0<\/span> \u8b1b\u6f14<\/strong>
\n1. \u5bae\u5ddd\u6b63\u7537. PET-CT\u306e\u9069\u5fdc\u3068\u6709\u7528\u6027. \u7b2c9\u56de\u4eca\u6cbb\u5e02\u533b\u5e2b\u4f1a\u533b\u5b66\u8b1b\u6f14\u4f1a (2007. 1, \u4eca\u6cbb\u5e02)
\n2. \u5bae\u5ddd\u6b63\u7537. \uff30\uff25\uff34\u691c\u8a3a\u306b\u3088\u308b\u304c\u3093\u306e\u65e9\u671f\u767a\u898b\u306b\u3064\u3044\u3066. \u611b\u5a9b\u770c\u793e\u4f1a\u798f\u7949\u5354\u8b70\u4f1a\u8b1b\u6f14\u4f1a (2007. 1, \u677e\u5c71\u5e02)
\n3. \u5bae\u5ddd\u6b63\u7537. \u80ba\u304c\u3093\u691c\u8a3a\u306b\u304a\u3051\u308bPET-CT\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066\u3000- CT\u691c\u8a3a\u306e\u5148\u306b\u3042\u308b\u3082\u306e -. \u611b\u5a9b\u770c\u533b\u5e2b\u4f1a\u80ba\u304c\u3093\u691c\u8a3a\u5f93\u4e8b\u8005\u8b1b\u7fd2\u4f1a (2007. 2, \u677e\u5c71\u5e02)
\n4. \u5bae\u5ddd\u6b63\u7537. PET-CT\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066. \u7b2c6\u56deCT\u30fbMRI\u7814\u7a76\u4f1a\u3048\u3072\u3081 (2007. 2, \u677e\u5c71\u5e02)
\n5. \u83ca\u6c60\u6075\u4e00. \u795e\u7d4c\u653e\u5c04\u7dda\u9818\u57df\u306b\u304a\u3051\u308b3.0 T MRI\u64ae\u5f71\u6280\u8853. \u611b\u5a9bCT\u30fbMRI\u7814\u7a76\u4f1a (2007. 2, \u677e\u5c71\u5e02)
\n6. \u6771\u91ce\u535a. \u5fc3\u75be\u60a3\u306b\u304a\u3051\u308b3\u30c6\u30b9\u30e9MRI\u306e\u6709\u7528\u6027. \u7b2c11\u56de\u611b\u5a9b\u5faa\u74b0\u5668\u6838\u533b\u5b66\u7814\u7a76\u4f1a (2007. 3, \u677e\u5c71\u5e02)
\n7. \u5bae\u5ddd\u6b63\u7537. PET\u306e\u73fe\u72b6\u3068\u305d\u306e\u5c06\u6765\u5c55\u671b. \u5357\u4e88\u753b\u50cf\u8a3a\u65ad\u7814\u7a76\u4f1a(SWEET)\u5b66\u8853\u8b1b\u6f14\u4f1a (2007. 3, \u5b87\u548c\u5cf6\u5e02)
\n8. \u6771\u91ce\u535a. \u5fc3\u7b4b\u30d0\u30a4\u30a2\u30d3\u30ea\u30c6\u30a3 -CT\u306b\u3066-. \u7b2c25\u56de\u5357\u4e88\u5faa\u74b0\u5668\u753b\u50cf\u7814\u7a76\u4f1a (2007. 4, \u516b\u5e61\u6d5c\u5e02)
\n9. \u6771\u91ce\u535a. \u30e9\u30a6\u30f3\u30c9\u30c6\u30fc\u30d6\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f38 \u5fc3\u7b4bviability\u306e\u8a55\u4fa1\u6cd5. \u7b2c71\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u96c6\u4f1a (2007. 4, \u795e\u6238\u5e02)
\n10. \u5bae\u5ddd\u6b63\u7537. PET\/CT\u306e\u9069\u5fdc\u3068\u6709\u7528\u6027. \u6e08\u751f\u4f1a\u897f\u6761\u75c5\u9662\u8a18\u5ff5\u8b1b\u6f14\u4f1a (2007. 6, \u897f\u6761\u5e02)
\n11. \u4e09\u6728\u3000\u5747. \u30b9\u30dd\u30fc\u30c4\u5916\u50b7\u30fb\u640d\u50b7\u306eMRI. \u677e\u5c71\u5e02\u533b\u5e2b\u4f1a (2007. 7, \u677e\u5c71\u5e02)
\n12. \u5c71\u672c\u5c1a\u5e78. \u9664\u67d3\u5b9f\u7fd2-\u6c5a\u67d3\u3092\u4f34\u3063\u305f\u5916\u50b7\u60a3\u8005\u306e\u53d6\u308a\u6271\u3044. \u5317\u6d77\u9053\u300c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u57fa\u790e\u8b1b\u5ea7\u2160\u300d (2007. 7, \u672d\u5e4c\u5e02)
\n13. \u6771\u91ce\u535a. \u5fc3\u81d3CT\u30fbMR\u306e\u767a\u5c55\u3068\u6838\u533b\u5b66\u306e\u91cd\u8981\u6027. \u7b2c27\u56de\u9999\u5ddd\u770c\u6838\u533b\u5b66\u8ac7\u8a71\u4f1a (2007. 7, \u9ad8\u677e\u5e02)
\n14. \u5c71\u672c\u5c1a\u5e78. \u60f3\u5b9a\u4e8b\u6545\u306e\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u3000\u57fa\u790e\u7de8\u30fb\u5fdc\u7528\u7de8. \u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u300c\u611b\u5a9b\u30d5\u30a9\u30fc\u30e9\u30e0\u300d (2007. 8, \u677e\u5c71\u5e02)
\n15. \u5c71\u672c\u5c1a\u5e78. \u9664\u67d3\u5b9f\u7fd2-\u6c5a\u67d3\u3092\u4f34\u3063\u305f\u5916\u50b7\u60a3\u8005\u306e\u53d6\u308a\u6271\u3044. \u611b\u5a9b\u770c\u300c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u57fa\u790e\u8b1b\u5ea7\u2160\u300d (2007. 9, \u677e\u5c71\u5e02)
\n16. \u5c71\u672c\u5c1a\u5e78. \u8a8d\u77e5\u75c7\u306e\u753b\u50cf\u8a3a\u65ad. \u516b\u5e61\u6d5c\u533b\u5e2b\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a (2007. 9, \u516b\u5e61\u6d5c\u5e02)
\n17. \u5bae\u5ddd\u6b63\u7537. PET\/CT\u88c5\u7f6e\u3092\u7528\u3044\u305f\u5fc3\u7b4bviability\u8a3a\u65ad. \u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u533a\u6559\u80b2\u7814\u4fee\u4f1a (2007. 9, \u677e\u5c71\u5e02)
\n18. \u516b\u6728\u3000\u5927. \u304a\u306a\u304b\u304c\u75db\u304f\u306a\u308b\u75c5\u6c17. \u7b2c\uff13\uff16\u56de\u5e02\u6c11\u516c\u958b\u8b1b\u5ea7\u3000 (2007. 9, \u897f\u6761\u5e02)
\n19. \u6771\u91ce\u535a. \u751f\u5b58\u80fd\u3068\u8aad\u5f71\u6cd5. \u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u4e2d\u56db\u56fd\u8b1b\u7fd2\u4f1a (2007. 9, \u677e\u5c71\u5e02)
\n20. \u6771\u91ce\u535a. \u30b7\u30f3\u30dd\u30b8\u30a6\u30e01 \u9ad8\u78c1\u5834MRI \u5fc3\u81d3\u306e3T MRI. \u7b2c35\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2007. 9, \u795e\u6238\u5e02)
\n21. \u6d25\u7530\u5b5d\u6cbb. 3\u6b21\u5143\u753b\u50cf\u3092\u7528\u3044\u305f\u8179\u90e8\u753b\u50cf\u8a3a\u65ad. \u6d88\u5316\u5668\u75c5\u5b66\u4f1a\u56db\u56fd\u652f\u90e8\u7b2c12\u4f1a\u6559\u80b2\u8b1b\u6f14\u4f1a (2007. 10, \u677e\u5c71\u5e02)
\n22. \u4ed9\u6ce2\u8cb4\u654f. \u8179\u90e8\u306eMRI. \u7b2c5\u56de\u611b\u5a9b\u770c\u81e8\u5e8a\u691c\u67fb\u6280\u5e2b\u4f1aMRI\u5206\u79d1\u4f1a\u7814\u4fee\u4f1a (2007. 10, \u5b87\u548c\u5cf6\u5e02)
\n23. \u6771\u91ce\u535a. \u30de\u30eb\u30c6\u30a3\u30e2\u30c0\u30ea\u30c6\u30a3\u5fc3\u81d3\u89e3\u6790. INNOVATIVE AZE 2007 TOKYO (2007. 10, \u6771\u4eac\u90fd)
\n24. \u83ca\u6c60\u6075\u4e00. \u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u9020\u5f71\u5264\u3068\u814e\u969c\u5bb3. \u8ee2\u79fb\u6027\u8133\u816b\u760d\u3092\u8003\u3048\u308b\u4f1a (2007. 11, \u677e\u5c71\u5e02)
\n25. \u5c71\u672c\u5c1a\u5e78. \u9664\u67d3\u5b9f\u7fd2-\u6c5a\u67d3\u3092\u4f34\u3063\u305f\u5916\u50b7\u60a3\u8005\u306e\u53d6\u308a\u6271\u3044. \u9e7f\u5150\u5cf6\u770c\u300c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u57fa\u790e\u8b1b\u5ea7\u2160\u300d (2007. 11, \u9e7f\u5150\u5cf6\u5e02)
\n26. \u6771\u91ce\u535a. \u5fc3\u81d3MRI\u306e\u767a\u5c55\u3068\u5c06\u6765\u6027. \u7b2c1\u56de\u5fb3\u5cf6\u5fc3\u81d3CT\u30fbMRI\u7814\u7a76\u4f1a (2007. 11, \u5fb3\u5cf6\u5e02)
\n27. \u6771\u91ce\u535a. \u30de\u30eb\u30c1\u30e2\u30c0\u30ea\u30c6\u30a3\u6642\u4ee3\u306b\u304a\u3051\u308b\u5fc3\u81d3\u6838\u533b\u5b66\u306e\u6b69\u3080\u3079\u304d\u9053 CT\u304a\u3088\u3073MRI\u306e\u767a\u5c55\u3068\u5fc3\u81d3\u6838\u533b\u5b66\u306e\u30b5\u30dd\u30fc\u30c8. \u7b2c47\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a (2007. 11, \u4ed9\u53f0\u5e02)
\n28. \u6751\u4e0a\u5fe0\u53f8. \u653e\u5c04\u7dda\u8a3a\u65ad\u5b66\u30fb\u3073\u307e\u3093\u6027\u80ba\u75be\u60a3. \u7b2c109\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a (2007. 12, \u5ca1\u5c71\u5e02)
\n29. \u6d25\u7530\u5b5d\u6cbb. \u8179\u90e8\uff13\u6b21\u5143\u753b\u50cf\u306e\u81e8\u5e8a\u5fdc\u7528\uff0d\u3088\u308a\u826f\u3044\u753b\u50cf\u3092\u63d0\u4f9b\u3059\u308b\u306b\u306f\uff0d. \u7b2c38\u56de\u9020\u5f71\u7814\u7a76\u4f1a (2007. 12, \u4eca\u6cbb\u5e02)<\/p>\n","protected":false},"excerpt":{"rendered":"

\u25a0 \u8ad6\u6587\u30fb\u8457\u66f8 \u539f\u8457\u8ad6\u6587 \u7dcf\u8aac\uff0c\u4ed6 \u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868 \u56fd\u969b\u5b66\u4f1a \u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09 \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09 \u25a0 \u8b1b\u6f14 ———————&#8 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-5442","post","type-post","status-publish","format-standard","hentry","category-20"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t